STOCK TITAN

Shuttle Pharmaceuticals Holdings, Inc. - SHPH STOCK NEWS

Welcome to our dedicated news page for Shuttle Pharmaceuticals Holdings (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on Shuttle Pharmaceuticals Holdings .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shuttle Pharmaceuticals Holdings 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shuttle Pharmaceuticals Holdings 's position in the market.

Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. has entered into an exclusive agreement to license intellectual property from Georgetown University for its predictive biomarker program for prostate cancer. The intellectual property consists of patent applications titled 'Predictive Biomarkers for Adverse Effects of Radiation Therapy.' Shuttle Pharma aims to develop a predictive diagnostic test for prostate cancer patients considering radiation therapy to assess treatment success or failure. The company believes this test would be cost-effective and provide clinicians and patients with a better understanding of the benefits and risks of radiation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings to present at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
conferences
-
Rhea-AI Summary
Shuttle Pharmaceuticals receives positive FDA feedback, paving the way for Phase 2 clinical trial of Ropidoxuridine in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
Rhea-AI Summary
Shuttle Pharmaceuticals to improve outcomes for prostate cancer patients through participation in health fair
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Shuttle Pharmaceuticals announces expansion of patent portfolio for its HDAC inhibitor platform technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. provides a corporate update, including progress on their lead drug candidate Ropidoxuridine. They are on track to commence Phase II clinical study in Q4 2023 and have completed the initial manufacturing campaign for the drug. They have also received FDA approval for a Type B pre-IND meeting. The company has moved into new laboratory and office space to accelerate development and diagnostic capabilities. Q2 2023 operating expenses totaled $1.5 million and cash balance was $8.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
Rhea-AI Summary
Shuttle Pharmaceuticals announces successful completion of initial manufacturing campaign for Ropidoxuridine API for upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. Company also receives approval for Type B pre-IND meeting with FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
Shuttle Pharmaceuticals Holdings, Inc.

Nasdaq:SHPH

SHPH Rankings

SHPH Stock Data

6.63M
9.55M
45.11%
2.12%
0.39%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
GAITHERSBURG